2015 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
03/12/15LabCorp Presents New Findings on HIV-1 and HCV Antiviral Drug Resistance at the 2015 Conference on Retroviruses and Opportunistic Infections
State of the art genetic and cell-based assays enable comprehensive characterization of resistance to new drugs and new drug classes BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 12, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Monogram Biosciences, Inc., a member of the LabCorp Specialty Testing Group, presented two new studies characterizing HIV-1 and HCV antiviral drug resistance at the 2015 Confer... 
Printer Friendly Version
03/11/15LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 11, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2015 to September 11, 2015, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
03/04/15LabCorp Contributes to Clinical Research Collaborations Directed at Advancing Treatment of Breast Cancer and Viral Hepatitis
Studies Promote Personalized Medicine and Advance Public Health Initiatives BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 4, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today highlighted clinical research efforts in oncology and viral hepatitis that demonstrate its commitment to novel diagnostic capabilities and unique bioinformatics resources to enhance patient care in today’s rapidly evolving healthcare system. ... 
Printer Friendly Version
03/03/15LabCorp is Scheduled to Present at the Barclays Capital 2015 Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 3, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Barclays Capital 2015 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 10, 2015 at 8:30 AM (Eastern Time). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay. ... 
Printer Friendly Version
02/20/15Laboratory Corporation of America® Holdings Announces 2014 Fourth Quarter and Full Year Results and Provides 2015 Guidance
Strong Q4 volume drives sales of $1.5 billion Diluted Q4 EPS of $1.39; Adjusted Q4 EPS of $1.65 Q4 Operating Cash Flow of approximately $214 million Q4 Free Cash Flow of approximately $167 million Announces Project LaunchPad, its enterprise-wide business process improvement initiative 2015 Adjusted EPS guidance of $7.35 - $7.70, inclusive of Covance as of... 
Printer Friendly Version
02/19/15LabCorp Completes Acquisition of Covance
Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 19, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the completion of its acquisition of Covance Inc., following its entry into a definitive purchase agreement on November 2, 2014. At closing, the purchase consideration was valued at ... 
Printer Friendly Version
02/10/15LabCorp Launches New Patient-Centric Diabetes Report
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 10, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of a new Diabetes Patient Education report for type 2 diabetes patients that aligns with the American Diabetes Association (Association) “Standards of Medical Care in Diabetes – 2015,” which was published as a supplement to the January 2015 edition of the Association’s Diabetes Care journal. LabCorp’... 
Printer Friendly Version
01/21/15LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior Notes due 2020 (the “2020 Notes”), $500,000,000 aggregate principal amount of 3.200% Senior Notes due 2022 (the “2022 Notes”), $1,000,000,000 aggregate prin... 
Printer Friendly Version
01/21/15LabCorp Announces Proposed Sale of Senior Notes
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30 years, respectively (the “Notes”). The Notes will be senior unsecured obligations and will rank equally with LabCorp’s existing and future senior unsecured debt. ... 
Printer Friendly Version
01/06/15LabCorp is Scheduled to Present at the 33rd Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 6, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp’s presentation is planned for Tuesday, January 13, 2015 at 2:00 p.m. (PST). A live audio webcast of the presentation will be available via the Compa... 
Printer Friendly Version
01/02/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee (Trustee)... 
Printer Friendly Version